Roche’s xCELLigence Cardio Instrument is a medium-throughput cell analyzer using impedance recording to monitor cardiac beating and cellular events in real time. The instrument features high resolution detection rate and frequency measurement technology driven by dedicated software. Unlike patch clamp recordings, this system monitors cardiac cell responsivity continuously in both short-term and long-term experiments.
Cells are cultured in Cardio E-Plates 96, specialized 96-well plates. Cardio E-Plates 96, manufactured with a microelectrode array at the bottom of each well, are otherwise identical to standard 96-well culture plates, and can be coated as cells require. Published reports confirm that the system’s continuous, robust and reproducible data stream is an accurate and powerful way to measure cardiac cell behaviour.
Cardiotoxicity is one of the most important parameters tested in drug development. The xCELLigence Cardio Instrument is available for immediate use with cardiomyocytes derived from human or mouse stem cells, to assess cardiac safety of drug candidates. The instrument provides online beating pattern analysis for quality control and standardized conditions. Data produced are complementary to existing cardiac safety testing methods. The RTCA Cardio’s added value is its ability to identify the need for more complex downstream testing, by pinpointing aberrant cardiac cell responses early in drug discovery. The instrument is easily integrated and combined with existing workflows, for pharma research applications in drug discovery, quality control, and cardiac preclinical safety testing.
For life science research only. Not for use in diagnostic procedures.
XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US.